Literature DB >> 6861794

Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.

G Maurer, E Schreier, S Delaborde, R Nufer, A P Shukla.   

Abstract

The disposition and biotransformation of bromocriptine were investigated in mouse, rat, dog, rhesus monkey and man following administration of the drug substance labelled with either tritium or carbon-14. The enteral absorption of bromocriptine was incomplete and amounted to 30-40% of the dose as estimated directly from the sum of biliary and urinary excretion of radioactive compounds in bile duct cannulated rats and monkeys. The main route of elimination was the bile (80-93% of the absorbed dose). Only 1 to 6% of the radioactive dose was recovered in urine of intact animals and man. Extensive biotransformation of bromocriptine is reflected by very complex metabolite profiles in all tested body fluids and by the almost complete absence of parent drug in urine and bile. Of the numerous drug-derived radioactive components seventeen could be identified. In animals the major urinary metabolites were 2-bromo-lysergic acid (7), its amide (3), and the respective isomers at position 8, metabolites 6 and 1. Bromolysergic acid (7) and bromoisolysergic acid (6) accounted for half of the radioactivity in human urine. In rat and monkey bile up to 40% of the radioactivity was associated with metabolites derived from the oxidation (hydroxylation, ring-opening) of the proline fragment (4, 5, 21-24, 29-31). The hydroxylated compounds were present in the form of conjugates with glucuronic acid. These were subsequently deconjugated in the intestine and recovered in the faeces as the free forms. The presence of the parent drug as a major component in rat plasma following intravenous administration and its absence after oral administration indicated that the elimination of bromocriptine proceeded almost entirely by metabolism in the liver. In vitro studies with isolated rat hepatocytes and 10.000 g supernatant of human liver confirmed the in vivo findings. Based on the structures of the identified metabolites it could be concluded that the biotransformation of bromocriptine in man occurred through the same principal pathways as in all investigated animal species.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861794     DOI: 10.1007/BF03189581

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Permanent bile duct cannulation in the monkey. A model for studying intestinal absorption.

Authors:  J Meszaros; F Nimmerfall; J Rosenthaler; H Weber
Journal:  Eur J Pharmacol       Date:  1975 Jun-Jul       Impact factor: 4.432

2.  Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine.

Authors:  F Nimmerfall; J Rosenthaler
Journal:  J Pharmacokinet Biopharm       Date:  1976-02

3.  Drug metabolism in human liver in vitro: establishment of a human liver bank.

Authors:  C von Bahr; C G Groth; H Jansson; G Lundgren; M Lind; H Glaumann
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

4.  Distribution and excretion in the rat and monkey of [82Br] bromocriptine.

Authors:  S P Markey; R W Colburn; I J Kopin; R L Aamodt
Journal:  J Pharmacol Exp Ther       Date:  1979-10       Impact factor: 4.030

5.  Transfer of bromocriptine across the blood-brain barrier in man.

Authors:  M L Friis; O B Paulson; M M Hertz
Journal:  Acta Neurol Scand       Date:  1979-03       Impact factor: 3.209

6.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

7.  Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites.

Authors:  G Maurer; E Schreier; S Delaborde; H R Loosli; R Nufer; A P Shukla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

Review 8.  Bromocriptine in Parkinsonism.

Authors:  I Pearce; J M Pearce
Journal:  Br Med J       Date:  1978-05-27

9.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

10.  Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.

Authors:  M L Friis; U Grøn; N E Larsen; H Pakkenberg; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

View more
  12 in total

1.  A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration.

Authors:  Tivadar Orban; Henri Leinonen; Tamar Getter; Zhiqian Dong; Wenyu Sun; Songqi Gao; Alexander Veenstra; Hossein Heidari-Torkabadi; Timothy S Kern; Philip D Kiser; Krzysztof Palczewski
Journal:  J Pharmacol Exp Ther       Date:  2017-11-21       Impact factor: 4.030

2.  High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4.

Authors:  Irina F Sevrioukova
Journal:  Biochemistry       Date:  2017-06-07       Impact factor: 3.162

3.  Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

4.  Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man.

Authors:  G Maurer; W Frick
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits.

Authors:  F L Tse; J M Jaffe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

Review 6.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

Review 7.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

8.  Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum.

Authors:  S Granveau-Renouf; D Valente; A Durocher; J M Grognet; E Ezan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.569

Review 9.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

Review 10.  Ergot alkaloids produced by endophytic fungi of the genus Epichloë.

Authors:  Philippe Guerre
Journal:  Toxins (Basel)       Date:  2015-03-06       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.